|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.076 - 0.134|
|52 Week Range||0.010 - 0.134|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 18, 2016 - Aug 19, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Data demonstrates MANF's role in modulating the immune microenvironment in the retina and its potential for treating retinal disorders Patent extends MANF Therapeutics' exclusivity for MANF and CDNF treatment ...
Allowed claims include the treatment of Type 1 and Type 2 Diabetes Once issued, patents extend exclusivity for MANF in the US into 2032 SAN FRANCISCO, Dec. 11, 2017-- Amarantus Bioscience Holdings, Inc., ...
Patents extend Eltoprazine Parkinson’ s disease LID treatment exclusivity into 2033. SAN FRANCISCO, Dec. 08, 2017-- Amarantus Bioscience Holdings, Inc., a US-based biotechnology holding company with wholly-owned ...
SAN FRANCISCO, Dec. 05, 2017-- Amarantus Bioscience Holdings, Inc., a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine ...
Amarantus Bioscience Holdings, Inc. (AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today provided a comprehensive corporate update to shareholders. The Company is focused on its capital restructuring efforts and restarting operations in Q1 2018. In Q2 2017, the Company completed the formation of two wholly-owned subsidiaries, Elto Pharma, Inc. and MANF Therapeutics, Inc. to focus on the development of Eltoprazine and MANF, respectively.
Amarantus Bioscience Holdings, Inc. (AMBS), a US-headquartered biotechnology holding company with wholly-owned subsidiaries developing first-in-class therapeutic products for symptomatic neurological conditions, life-threatening orphan dermatologic conditions, and orphan retinal diseases, today announced that the Company has entered into binding agreements (Binding LOIs) with holders of a controlling majority of its senior secured convertible debt (Old Debt) and convertible preferred (Old Preferred) securities to forbear default provisions in those agreements, cease the conversion into common shares of Old Debt and Old Preferred and raise up to $500,000 in new funding to prepare the Company for the restart of operations in 2018. As part of the Bindings LOIs, approximately $975,440 in first-priority lien senior secured debt (Senior Debt) held by a Manhattan-based family office will be extinguished via the periodic issuance of common shares throughout the course of the next several months.
Avant Diagnostics, Inc. ("Avant" or the "Company") (AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, today announced newly appointed President & CEO Philippe Goix delivered an address to shareholders outlining his assessment of the Company's potential and the path forward the Company intends to take in order to succeed in commercializing and revamping the Company's proprietary technologies.
GAITHERSBURG, Maryland , July 18, 2017 /PRNewswire/ -- Two thirds of all breast cancer (BC) tumors are estrogen receptor positive (ER)+ ER+ BC patients have mixed responses to endocrine therapy Research ...
Avant Diagnostics, Inc. ("Avant") (AVDX), an oncology-focused Healthcare-IT company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, acquired an exclusive option to license the patient-delivery technology platform from Genetic Health Solution ("GHS", website: http://www.genetichealthsolution.com). GHS is a functional medicine practice that specializes in the aggregation and analysis of advanced biomarker testing data to provide tailored product recommendations for health optimization.
SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Eltoprazine has successfully completed proof-of-concept Phase 2 human clinical studies in Adult ADHD, Alzheimer ' s Aggression and Parkinson ' s LID Elto ...
On February 27, 2017, Amarantus BioScience Holdings, Inc. (AMBS) ("Amarantus"), a US-headquartered biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced it had entered into a non-binding Letter of Intent ("LOI") with SeD Biomedical, Inc. ("SeD Biomedical"), a Singapore-based subsidiary of Singapore eDevelopment Limited (40V.SI)("SeD"), that is focused in the area of biomedical product development, where Amarantus may acquire up to four of SeD Biomedical's biotechnology platforms. SeD Biomedical and SeD are under the control of SeD's CEO and largest shareholder Mr. Chan Heng Fai. The LOI came as part of Amarantus' overall restructuring plan initiated in November of 2016.
SINGAPORE and SAN FRANCISCO, February 27, 2017 /PRNewswire/ -- Amarantus evaluating four Se D BioMedical assets for potential acquisition into its portfolio of biotechnology assets LOI contemplates capital ...
Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today, with great sadness, announced the death of biotechnology legend Dr. Joseph Rubinfeld, who was an independent director of the Company. Dr. Rubinfeld is survived by his wife, Loretta, and children Bonnie, Randee, Susan and Steven and their respective families.